DexCom (DXCM) Expected to Announce Earnings on Thursday

DexCom (NASDAQ:DXCM) is expected to release its Q3 2025 results after the market closes on Thursday, October 30th. Analysts expect DexCom to post earnings of $0.57 per share and revenue of $1.1784 billion for the quarter. DexCom has set its FY 2025 guidance at EPS.Interested persons can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, October 30, 2025 at 4:30 PM ET.

DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter in the prior year, the firm earned $0.43 EPS. DexCom’s quarterly revenue was up 15.2% on a year-over-year basis. On average, analysts expect DexCom to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

DexCom Price Performance

NASDAQ DXCM opened at $70.63 on Tuesday. The company has a 50-day moving average price of $72.17 and a two-hundred day moving average price of $78.00. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The stock has a market cap of $27.70 billion, a price-to-earnings ratio of 49.05, a price-to-earnings-growth ratio of 1.48 and a beta of 1.47. DexCom has a 52 week low of $57.52 and a 52 week high of $93.25.

Insider Buying and Selling at DexCom

In related news, Director Kyle Malady sold 667 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $80.86, for a total transaction of $53,933.62. Following the completion of the sale, the director directly owned 22,667 shares in the company, valued at approximately $1,832,853.62. This trade represents a 2.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Sadie Stern sold 1,466 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total transaction of $117,280.00. Following the sale, the executive vice president owned 105,223 shares of the company’s stock, valued at $8,417,840. The trade was a 1.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,383 shares of company stock valued at $434,274. 0.32% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On DexCom

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its stake in DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after purchasing an additional 11,946 shares during the period. Sone Capital Management LLC acquired a new position in DexCom in the 2nd quarter worth approximately $4,625,000. Captrust Financial Advisors boosted its stake in DexCom by 12.4% in the 2nd quarter. Captrust Financial Advisors now owns 33,235 shares of the medical device company’s stock worth $2,901,000 after purchasing an additional 3,661 shares during the period. NewEdge Advisors LLC lifted its position in DexCom by 1.4% in the 2nd quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock worth $1,681,000 after buying an additional 258 shares in the last quarter. Finally, Vident Advisory LLC lifted its position in DexCom by 8.1% in the 2nd quarter. Vident Advisory LLC now owns 8,381 shares of the medical device company’s stock worth $732,000 after buying an additional 626 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on DXCM shares. Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 10th. Truist Financial decreased their price objective on shares of DexCom from $102.00 to $94.00 and set a “buy” rating for the company in a report on Wednesday, October 15th. Raymond James Financial increased their price objective on shares of DexCom from $99.00 to $102.00 and gave the company a “strong-buy” rating in a report on Thursday, July 31st. Argus started coverage on shares of DexCom in a report on Thursday, August 21st. They issued a “buy” rating and a $100.00 price objective for the company. Finally, Oppenheimer cut shares of DexCom from an “outperform” rating to a “market perform” rating in a report on Monday, September 8th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $97.19.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.